| Literature DB >> 29107952 |
Maddalena A Wu1, Francesco Casella1, Francesca Perego1, Chiara Suffritti1, Nada Afifi Afifi1, Eleonora Tobaldini2, Andrea Zanichelli1, Chiara Cogliati1, Nicola Montano2, Marco Cicardi1.
Abstract
BACKGROUND: Attacks of Hereditary Angioedema due to C1-inhibitor deficiency (C1-INH-HAE)are often triggered by stressful events/hormonal changes.Entities:
Mesh:
Year: 2017 PMID: 29107952 PMCID: PMC5673184 DOI: 10.1371/journal.pone.0187110
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of patients and controls enrolled in the study.
| Patient Characteristics | Control Characteristics | |||
|---|---|---|---|---|
| Whole cohort (23 patients) | Cohort suitable for HRV analysis (20 patients) | Whole cohort (24 controls) | Cohort suitable for HRV analysis (19 controls) | |
| Female | 17 | 14 | 16 | 14 |
| Male | 6 | 6 | 8 | 5 |
| Mean age in the whole cohort | 47.5±11.4 | 49±11.4 | 45.3±10.6 | 47±10.6 |
| Mean age in males | 38.3±9.0 | 38.3±9.0 | 43.0±11.1 | 47.2±12.1 |
| Mean age in females | 50.7±10.5 | 53.6±9.2 | 47.4±9.9 | 47.5±10.6 |
| 23.4±4.2 | 23.7±4.4 | 23.8±3.1 | 23.8±3.3 | |
| Type I | 20 | 17 | N/A | N/A |
| Type II | 3 | 3 | N/A | N/A |
| None | 6 | 5 | N/A | N/A |
| Lanadelumab | 2 | 1 | N/A | N/A |
| Cinryze | 1 | 1 | N/A | N/A |
| Recombinant C1- inhibitor | 1 | 1 | N/A | N/A |
| Androgens | 13 | 12 | N/A | N/A |
HRV parameters of 20 C1-INH-HAE patients and 19 controls (rest and tilt).
| Mean±SD | Patients vs controls at R | Mean±SD | Patients vs controls after T | R vs T in patients and in controls | ||
|---|---|---|---|---|---|---|
| C1-INH-HAE-patients | 71.2±12.6 | N.S. | 81.6±10.8 | N.S. | <0.001 | |
| Controls | 72.7±13.5 | 83.3±11.9 | <0.001 | |||
| C1-INH-HAE-patients | 872.3±147.9 | N.S. | 795.5±108.7 | N.S. | <0.05 | |
| Controls | 868.6±138.6 | 769.7±204.8 | <0.001 | |||
| C1-INH-HAE-patients | 57.7±24.9 | N.S. | 69.7±26.1 | N.S. | <0.05 | |
| Controls | 51.5±21.2 | 78.0±20.7 | <0.001 | |||
| C1-INH-HAE-patients | 26.3±19.7 | N.S. | 23.0±18.4 | 0.05 | N.S. | |
| Controls | 31.5±17.4 | 13.2±12.1 | <0.001 | |||
| C1-INH-HAE-patients | 5.3±8.3 | N.S. | 12.8±21.6 | N.S. | N.S. | |
| Controls | 2.7±2.9 | 16.5±18.7 | <0.01 | |||
| C1-INH-HAE-patients | 134.0±19.0 | <0.001 | 141.4±28.8 | 0.01 | N.S. | |
| Controls | 114.9±9.8 | 121.7±17.3 | <0.05 | |||
| C1-INH-HAE-patients | 17.8±2.9 | N.S. | 18.2±5.8 | N.S. | N.S. | |
| Controls | 18.3±2.7 | 18.6±4.2 | N.S. | |||
| C1-INH-HAE-patients | 0.29±0.04 | N.S. | 0.30±0.06 | N.S. | N.S. | |
| Controls | 0.30±0.04 | 0.30±0.08 | N.S. |
Biochemical parameters of 23 C1-INH-HAE patients and 24 controls (rest and tilt).
| Parameter | Subjects | Rest | p | Tilt | p | p |
|---|---|---|---|---|---|---|
| Mean ± SD | Patients vs controls at R | Mean ± SD | Patients vs controls after T | R vs T in patients and in controls | ||
| C1-INH-HAE-patients | 19.2 ± 13.1 | <0.001 | 24.1 ±13.8 | <0.001 | <0.01 | |
| Controls | 86.5 ± 27.5 | 94.7 ± 24.3 | <0.05 | |||
| C1-INH-HAE-patients | 24.0 ± 34.5 | <0.001 | 27.6 ± 33.4 | <0.001 | <0.05 | |
| Controls | 100.7 ± 10.6 | 102.2 ± 7.8 | N.S. | |||
| C1-INH-HAE-patients | 100.5 ± 6.1 | N.S. | 100.2 ± 7.0 | N.S. | N.S. | |
| Controls | 102.9 ± 5.0 | 103.3± 5.0 | N.S. | |||
| C1-INH-HAE-patients | 29.6 ± 27.3 | <0.001 | 30.3 ± 25.3 | <0.001 | N.S. | |
| Controls | 102.1 ± 23.0 | 105.0 ± 21.0 | N.S. | |||
| C1-INH-HAE-patients | 47.1 ± 7.8 | <0.001 | 49.5 ± 7.5 | <0.001 | 0.01 | |
| Controls | 38.7 ± 7.2 | 40.0 ± 6.1 | N.S. |